ClinicalTrials.gg
Not yet recruitingNCT07270965Updated Nov 16, 2026

Moisturization and Skin Hydration Study

An interventional study of Moisturizing while in shower/bath and Moisturizing after towel drying in Atopic Dermatitis (AD) and Atopic Dermatitis (Eczema), sponsored by University of British Columbia. Not yet recruiting at 1 site in Canada. Open to participants aged 12 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-11-16.

Sponsored by University of British Columbia · Not applicable, Interventional, and Prevention

How we know

Updated Nov 16, 2026Start date movedPrimary completion moved+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
12 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 225 studies in Dermatitis, Atopic with a site in Canada — 18 open to participants now, 44 under way, 13 of them phase 3. Dermatitis, Atopic · Canada.

Planned enrollment
193rd of 207
30 · median 206
Started
2027
the only one that year
No phase
9 of 225
2 open now
Primary completion
2027-05
later than 19 of 43 live
Registered
217th of 225
by date

Among the 225 studies in Dermatitis, Atopic with a site in Canada, this one is the 193rd largest by planned enrollment of the 207 interventional ones that give a count, is the only one that started in 2027, is one of 9 with no phase, reaches primary completion later than 19 of the 43 other live ones, and was the 217th registered.

Dermatitis, Atopic

1,596 studies on the registry are indexed under Dermatitis, Atopic; 289 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

18 of the 225 studies in Dermatitis, Atopic with a site in Canada are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 195 Dermatitis, Atopic studies recruiting now, 84 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 52 take healthy volunteers.

This study: 12 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 225 studies in Dermatitis, Atopic with a site in Canada, or all of them as a file.
02

Study summary

Skin moisturization is important for patients with atopic dermatitis, commonly known as eczema. Moisturizing right after bathing is widely accepted as the best method to keep skin hydrated. However, there is conflicting research on the timing of moisturizing. The goal of this clinical study is to evaluate the preference of moisturizing while showering/bathing compared to after towel drying in adolescents aged 12-18 with eczema. The main question it aims to answer are:

  • Which moisturization technique is preferred: while showering/bathing or after towel drying?
  • How do these techniques affect investigator-assessed eczema severity, patient-reported itch scores, and objective skin hydration measurements?

Researchers will compare applying moisturizer while in the shower/bath to after towel drying and to which technique is preferred among participants and if there are different effects on eczema and skin hydration.

Participants will:

  • Apply moisturizer while showering/bathing for one month and after towel drying for one month.
  • Complete questionnaires on moisturization technique, skin feel, and itchiness.
  • Undergo skin hydration measurements using a Corneometer® CM825 device.
03

Conditions studied

  • Atopic Dermatitis (AD)
  • Atopic Dermatitis (Eczema)

Keywords

  • Atopic Dermatitis
  • Eczema
  • AD
  • Moisturizer
  • Cream
  • Skin Hydration
04

Who can participate

Ages eligible
12 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants must have a diagnosis of atopic dermatitis/eczema.
  • Participants must be between the age of 12-18.
  • Participants must be able to bathe independently.
  • Participants will be English speaking and able to complete questionnaires.

Exclusion criteria

Exclusion Criteria:

  • Participants who use topical between one inch above the wrist and 1 inch below the elbow from 1 month on both arms prior to the study until the final visit.
  • Participants who have a known allergy to the moisturizer cream (Cerave Moisturizing Cream) provided.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Moisturizing while in shower/bath

    Behavioral: Moisturizing while in shower/bath

  • Experimental
    Moisturizing after towel drying

    Behavioral: Moisturizing after towel drying

Interventions

  • BehavioralMoisturizing while in shower/bath

    Applying moisturizer in the shower/bath.

  • BehavioralMoisturizing after towel drying

    Applying moisturizer out of the shower/bath after towel drying.

06

What researchers measure

Primary outcomes

  1. Proportion of Participants Preferring Each Moisturization Technique

    Participant reported preference of moisturization technique

    Time frame: Through study completion, an average of 2 months.

Secondary outcomes

  1. Skin Hydration Level

    Skin electrical capacitance measured using Corneometer® CM825 as an indicator of skin hydration.

    Time frame: Through study completion, an average of 2 months.

Other outcomes

  1. Eczema Severity Score

    Eczema severity will be assessed by clinicians using the Validated Investigator Global Assessment Scale for Atopic Dermatitis (vIGA-AD™). Scores range from 1 to 4, with higher scores indicating more severe eczema/atopic dermatitis (worse outcome).

    Time frame: Through study completion, an average of 2 months.

  2. Itch Intensity

    Itch intensity will be assessed using a patient-reported Numeric Rating Scale (NRS) ranging from 1 to 10, where higher scores indicate greater itch severity (worse outcome). Participants will report both average itch and worst itch experienced within the past 24 hours.

    Time frame: Through study completion, an average of 2 months.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No — Individual participant data will not be shared, but aggregated data from all participants will be shared.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2027; primary completion for May 2027, 4 months later.

Of 114 non-industry interventional studies with no phase under Dermatitis, Atopic, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 43. This study's planned 4 months is below that.

Counting every sponsor, half of 183 studies reached it within 15 months; a quarter within 7 and three quarters within 34.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 16, 2026: start Dec 2025 → Jan 2027, primary completion Dec 2026 → May 2027 and completion Dec 2026 → Jun 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 21, 2025
First posted
Dec 8, 2025
StartEst.
Jan 2027was Dec 2025
Primary completionEst.
May 2027was Dec 2026
CompletionEst.
Jun 2027was Dec 2026
Last update
Nov 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Start date
Dec 2025→Jan 2027
Nov 16, 2026
Primary completion
Dec 2026→May 2027
Nov 16, 2026
Study completion
Dec 2026→Jun 2027
Nov 16, 2026
Show all 1 update
  1. Nov 16, 2026
    Start date Dec 2025→Jan 2027
    Primary completion Dec 2026→May 2027
    Study completion Dec 2026→Jun 2027
    + 1 other change: responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07270965
Responsible party
Wingfield Rehmus (Principal Investigator, University of British Columbia) — Principal investigator
First posted
Dec 8, 2025
Start date
Jan 2027 (estimated)
Primary completion
May 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
Nov 16, 2026

Study contacts

Wingfield Rehmus, MD, MPH
Contact
dermatologyresearch@cw.bc.ca
1-604-875-2606

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Nov 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion